DYNEX CAPITAL, INC. financials

  1. Home
  2. Financials
  3. DX
DX CIK 0000826675

Source: EDGAR filings · Built 2026-06-02T02:51:49Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Debt — — — -277.79M -278.87M -174.22M
Return on Equity (ROE) 12.96% 9.61% -0.70% 15.88% 13.26% 28.03%
Return on Assets (ROA) 1.84% 1.39% -0.10% 3.97% 2.81% 5.74%
Debt-to-Equity — — — 0.06× 0.11× 0.19×
Cash Conversion Ratio 0.38× 0.13× -10.15× 0.88× 1.44× 0.98×
Accruals Ratio 0.01× 0.01× -0.01× 0.00× -0.01× 0.00×

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 5.67× 8.49× — 4.01× 6.01× 2.57×
P/B 0.99× 0.90× 0.82× 0.76× 0.79× 0.67×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Expenses 53.05M 36.50M 32.88M 33.84M 25.43M 22.14M
Net Income (Loss) Attributable to Parent 319.07M 113.90M -6.13M 143.16M 102.26M 177.53M
Earnings Per Share, Basic $2.49 $1.50 $-0.25 $3.19 $2.79 $6.93
Weighted Average Number of Shares Outstanding, Basic 124.13M 70.77M 54.81M 42.49M 32.60M 23.11M
Earnings Per Share, Diluted $2.47 $1.49 $-0.25 $3.17 $2.78 $6.93
Weighted Average Number of Shares Outstanding, Diluted 125.07M 71.26M 54.81M 42.74M 32.76M 23.11M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 531.04M 377.10M 119.64M 332.04M 366.02M 295.60M
Assets 17.34B 8.18B 6.37B 3.61B 3.64B 3.09B
Liabilities 14.88B 7.00B 5.50B 2.70B 2.87B 2.46B
Common Stock, Shares, Outstanding 174.81M 84.49M 57.04M 53.64M 36.67M 23.70M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 120.82M 14.39M 62.20M 126.35M 146.97M 173.95M
Net Cash Provided by (Used in) Investing Activities -8.07B -1.03B -2.96B -65.44M -555.38M 2.35B
Payments for Repurchase of Common Stock — — — 0 0 372.00K
Payments of Dividends 246.60M 117.84M 93.04M 72.37M 58.90M 52.44M
Net Cash Provided by (Used in) Financing Activities 8.26B 1.40B 2.69B -32.34M 519.98M -2.35B

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (DX CIK 0000826675), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

OPEN

Opendoor Technologies Inc.

ZVRA

Zevra Therapeutics, Inc.

FBNC

FIRST BANCORP